cancer vaccines

News

Data builds behind Moderna's skin cancer vaccine

Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.

News

Time For Change in Scrabble letters on a cork background

Nykode changes tack after Roche exits partnership

Hit by the loss of a partnership with Roche's Genentech unit last year, Norway's Nykode has narrowed its R&D focus.

News

Scancell points to 'strong' melanoma vaccine data

Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.

News

Scancell taps into NHS matchmaking service for cancer trial

Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.

News

GSK backs £50m Oxford University cancer vaccine programme

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

Data builds behind Moderna's skin cancer vaccine

Nykode changes tack after Roche exits partnership

Scancell points to 'strong' melanoma vaccine data

Scancell taps into NHS matchmaking service for cancer trial

GSK backs £50m Oxford University cancer vaccine programme

MSD, Moderna start phase 3 adjuvant lung cancer trial

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

cancer vaccines

Editor's Picks